SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $21.3M $16.1M $34.1M $45.8M $104.5M $93.0M $41.9M $11.4M
Accounts Receivable — — $0 $2.1M $861.0K $0 — —
Inventory — — $0 $899.0K $463.0K $0 — —
Total Current Assets $40.4M $72.2M $102.1M $79.1M $109.4M $98.2M $52.4M $51.5M
Property, Plant & Equipment — — — — $113.0K $298.0K $405.0K $516.0K
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — $0 $408.0K $1.1M $0 — —
Total Assets $59.0M $90.6M $128.4M $87.8M $119.8M $102.5M $57.2M $53.2M
Liabilities
Accounts Payable $2.2M $4.6M $7.1M $5.9M $7.8M $4.6M $7.2M $3.7M
Total Current Liabilities $5.7M $24.1M $16.3M $17.6M $13.6M $26.4M $11.0M $5.9M
Long-Term Debt — — — — $34.4M — $0 $15.1M
Total Liabilities $9.7M $35.6M $55.5M $84.6M $78.6M $79.8M $44.3M $21.9M
Stockholders' Equity
Retained Earnings $-385.1M $-376.5M $-355.2M $-422.3M $-359.5M $-326.6M $-271.4M $-217.7M
Total Stockholders' Equity $49.4M $55.1M $73.0M $3.2M $41.3M $22.8M $12.9M $31.2M
← Newer Page 1 of 2 Older →